Squarepoint
KNSA icon

Squarepoint’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Squarepoint’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.61M Buy
158,093
+72,911
+86% +$3.23M 0.01% 1225
2025
Q4 		$3.51M Sell
85,182
-16
-0% -$642 ﹤0.01% 1685
2025
Q3 		$3.31M Sell
85,198
-331,374
-80% -$10.8M ﹤0.01% 1718
2025
Q2 		$11.5M Buy
416,572
+271,005
+186% +$6.9M 0.01% 1002
2025
Q1 		$3.23M Buy
145,567
+118,759
+443% +$2.44M ﹤0.01% 1728
2024
Q4 		$530K Buy
+26,808
New +$612K ﹤0.01% 3679
2024
Q3 		– Sell
-24,845
Closed -$464K – 4407
2024
Q2 		$464K Buy
24,845
+11,344
+84% +$213K ﹤0.01% 3135
2024
Q1 		$266K Sell
13,501
-9,267
-41% -$181K ﹤0.01% 3458
2023
Q4 		$399K Sell
22,768
-24,731
-52% -$406K ﹤0.01% 3173
2023
Q3 		$825K Sell
47,499
-2,975
-6% -$50.1K ﹤0.01% 2454
2023
Q2 		$711K Buy
50,474
+30,929
+158% +$414K ﹤0.01% 2410
2023
Q1 		$210K Buy
19,545
+7,382
+61% +$97.3K ﹤0.01% 2778
2022
Q4 		$182K Buy
+12,163
New +$177K ﹤0.01% 2819
2021
Q3 		– Sell
-28,744
Closed -$400K – 3179
2021
Q2 		$400K Buy
+28,744
New +$437K ﹤0.01% 2302
2021
Q1 		– Sell
-53,075
Closed -$938K – 3368
2020
Q4 		$938K Buy
53,075
+15,484
+41% +$272K 0.01% 1379
2020
Q3 		$576K Buy
37,591
+14,559
+63% +$273K 0.01% 1330
2020
Q2 		$587K Buy
23,032
+12,633
+121% +$264K 0.01% 1221
2020
Q1 		$161K Sell
10,399
-110,423
-91% -$1.73M ﹤0.01% 1542
2019
Q4 		$1.34M Buy
120,822
+91,926
+318% +$799K 0.01% 1158
2019
Q3 		$246K Sell
28,896
-9,504
-25% -$105K ﹤0.01% 1991
2019
Q2 		$520K Buy
38,400
+11,860
+45% +$184K 0.01% 1639
2019
Q1 		$479K Buy
26,540
+11,788
+80% +$228K 0.01% 1506
2018
Q4 		$414K Buy
14,752
+2,223
+18% +$46.4K ﹤0.01% 1350
2018
Q3 		$319K Buy
+12,529
New +$244K ﹤0.01% 1510

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Squarepoint's KNSA Position: Q1 2026 in Review

Squarepoint increased its Kiniksa Pharmaceuticals (KNSA) stake by 86% in Q1 2026, buying an estimated $3.23M and bringing the position to 158,093 shares worth $7.61M. The position accounts for 0.01% of the portfolio, ranked #1225.

Squarepoint first reported a position in KNSA in Q3 2018 and has held it in 24 quarters since. The position peaked at $11.5M in Q2 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Squarepoint held 158,093 shares of Kiniksa Pharmaceuticals worth $7.61M as of Q1 2026.
  • Squarepoint bought 72,911 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $3.23M.
  • Kiniksa Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1225 holding.
  • Squarepoint first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 24 quarters since.
  • Squarepoint's Kiniksa Pharmaceuticals position peaked at $11.5M in Q2 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.